SG Americas Securities’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $352K | Buy |
42,394
+1,865
| +5% | +$19.3K | ﹤0.01% | 2373 |
|
|
2025
Q4 | $501K | Buy |
40,529
+25,207
| +165% | +$270K | ﹤0.01% | 2494 |
|
|
2025
Q3 | $135K | Buy |
+15,322
| New | +$119K | ﹤0.01% | 2953 |
|
|
2024
Q4 | – | Sell |
-60,724
| Closed | -$507K | – | 3256 |
|
|
2024
Q3 | $507K | Buy |
60,724
+43,378
| +250% | +$394K | ﹤0.01% | 1678 |
|
|
2024
Q2 | $118K | Sell |
17,346
-41,375
| -70% | -$178K | ﹤0.01% | 2451 |
|
|
2024
Q1 | $149K | Sell |
58,721
-7,290
| -11% | -$16.4K | ﹤0.01% | 2211 |
|
|
2023
Q4 | $158K | Buy |
66,011
+41,712
| +172% | +$98K | ﹤0.01% | 2374 |
|
|
2023
Q3 | $83K | Buy |
+24,299
| New | +$135K | ﹤0.01% | 2840 |
|
|
2023
Q2 | – | Sell |
-10,855
| Closed | -$112K | – | 2510 |
|
|
2023
Q1 | $112K | Buy |
+10,855
| New | +$131K | ﹤0.01% | 2833 |
|
|
2022
Q3 | – | Sell |
-47,864
| Closed | -$1.49M | – | 3274 |
|
|
2022
Q2 | $1.49M | Buy |
47,864
+16,738
| +54% | +$571K | 0.02% | 949 |
|
|
2022
Q1 | $1.28M | Sell |
31,126
-23,155
| -43% | -$1.02M | 0.01% | 1245 |
|
|
2021
Q4 | $2.36M | Buy |
54,281
+31,284
| +136% | +$1.42M | 0.01% | 961 |
|
|
2021
Q3 | $1.15M | Buy |
22,997
+18,121
| +372% | +$1.1M | 0.01% | 1785 |
|
|
2021
Q2 | $307K | Sell |
4,876
-8,341
| -63% | -$536K | ﹤0.01% | 2159 |
|
|
2021
Q1 | $1.23M | Sell |
13,217
-2,901
| -18% | -$297K | 0.01% | 1390 |
|
|
2020
Q4 | $1.44M | Buy |
16,118
+8,030
| +99% | +$737K | 0.01% | 1302 |
|
|
2020
Q3 | $836K | Buy |
8,088
+4,822
| +148% | +$520K | 0.01% | 1294 |
|
|
2020
Q2 | $258K | Sell |
3,266
-16,165
| -83% | -$1.2M | ﹤0.01% | 2634 |
|
|
2020
Q1 | $1.12M | Buy |
19,431
+15,935
| +456% | +$918K | 0.01% | 1211 |
|
|
2019
Q4 | $189K | Sell |
3,496
-116
| -3% | -$6.29K | ﹤0.01% | 2513 |
|
|
2019
Q3 | $189K | Buy |
3,612
+538
| +18% | +$25.1K | ﹤0.01% | 2383 |
|
|
2019
Q2 | $149K | Sell |
3,074
-2,700
| -47% | -$129K | ﹤0.01% | 2582 |
|
|
2019
Q1 | $292K | Sell |
5,774
-10,985
| -66% | -$648K | ﹤0.01% | 2288 |
|
|
2018
Q4 | $993K | Buy |
16,759
+14,832
| +770% | +$956K | 0.01% | 1330 |
|
|
2018
Q3 | $127K | Sell |
1,927
-1,879
| -49% | -$110K | ﹤0.01% | 2767 |
|
|
2018
Q2 | $192K | Buy |
3,806
+563
| +17% | +$29.3K | ﹤0.01% | 2625 |
|
|
2018
Q1 | $171K | Buy |
+3,243
| New | +$162K | ﹤0.01% | 2533 |
|
|
2017
Q4 | – | Sell |
-4,999
| Closed | -$202K | – | 3291 |
|
|
2017
Q3 | $202K | Buy |
+4,999
| New | +$181K | ﹤0.01% | 2576 |
|
|
2017
Q1 | – | Sell |
-8,474
| Closed | -$278K | – | 3331 |
|
|
2016
Q4 | $278K | Buy |
8,474
+682
| +9% | +$20.4K | ﹤0.01% | 2095 |
|
|
2016
Q3 | $246K | Buy |
+7,792
| New | +$226K | ﹤0.01% | 2309 |
|
|
2015
Q3 | – | Sell |
-4,196
| Closed | -$138K | – | 2243 |
|
|
2015
Q2 | $138K | Buy |
+4,196
| New | +$130K | ﹤0.01% | 2176 |
|
|
2015
Q1 | – | Sell |
-7,364
| Closed | -$201K | – | 2647 |
|
|
2014
Q4 | $201K | Buy |
+7,364
| New | +$175K | ﹤0.01% | 2413 |
|
Other funds holding EBS
VCM
PCM
VPM
SG Americas Securities's EBS Position: Q1 2026 in Review
SG Americas Securities increased its Emergent Biosolutions (EBS) stake by 4.6% in Q1 2026, buying an estimated $19.3K and bringing the position to 42,394 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #2373.
SG Americas Securities first reported a position in EBS in Q4 2014 and has held it in 32 quarters since. The position peaked at $2.36M in Q4 2021. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.
- SG Americas Securities held 42,394 shares of Emergent Biosolutions worth $352K as of Q1 2026.
- SG Americas Securities bought 1,865 Emergent Biosolutions shares in Q1 2026, an estimated $19.3K.
- Emergent Biosolutions made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2373 holding.
- SG Americas Securities first reported a position in Emergent Biosolutions in Q4 2014 and has held it in 32 quarters since.
- SG Americas Securities's Emergent Biosolutions position peaked at $2.36M in Q4 2021.
- 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.
Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.